Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere In-Licenses China Rights to Clinical-Stage Stroke Treatment

publication date: Nov 5, 2019

Simcere Pharma of Nanjing in-licensed greater China rights for a clinical stage drug that treats cerebral edema following stroke from Aeromics of New Haven, Connecticut. AER-271 is a first-in-class IV prodrug that delivers an inhibitor of Aquaporin-4, a water channel protein that facilitates brain swelling after ischemic strokes. It has completed an Aeromics-led Phase I trial. Aeromics will receive an upfront payment and additional development, regulatory and commercial milestones, plus tiered royalties on net sales. Simcere already markets Bicun, an edaravone free-radical scavenger to prevent strokes. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital